NeuroOne Medical Technologies Corporation
NMTC · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $9 | $3 | $2 | $0 |
| % Growth | 163.5% | 76.9% | 1,040.7% | – |
| Cost of Goods Sold | $4 | $2 | $1 | $0 |
| Gross Profit | $5 | $1 | $0 | -$0 |
| % Margin | 56.5% | 31.3% | 23.4% | -41.4% |
| R&D Expenses | $5 | $5 | $7 | $5 |
| G&A Expenses | $0 | $8 | $7 | $7 |
| SG&A Expenses | $7 | $8 | $7 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$1 | $0 |
| Operating Expenses | $12 | $13 | $12 | $10 |
| Operating Income | -$4 | -$12 | -$12 | -$10 |
| % Margin | -46.5% | -344.3% | -612.3% | -5,860.2% |
| Other Income/Exp. Net | $1 | -$0 | $0 | $0 |
| Pre-Tax Income | -$4 | -$12 | -$12 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$12 | -$12 | -$10 |
| % Margin | -39.6% | -356.7% | -607.4% | -5,842% |
| EPS | -0.09 | -0.46 | -0.65 | -0.63 |
| % Growth | 80.4% | 29.2% | -3.2% | – |
| EPS Diluted | -0.09 | -0.46 | -0.65 | -0.63 |
| Weighted Avg Shares Out | 40 | 27 | 18 | 16 |
| Weighted Avg Shares Out Dil | 40 | 27 | 18 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$12 | -$12 | -$10 |
| % Margin | -46.5% | -343% | -602.1% | -5,790.9% |